|
Species Reactivity |
Human |
|
Clone |
otilimab |
|
Source/Isotype |
Human IgG1 (KEEM) lambda2 |
|
Application |
Bioactivity-ELISA |
|
Target |
Detects CSF2 |
|
Gene |
CSF2 |
|
Other Names |
CSF, GMCSF |
|
Gene ID |
1437 (human) |
|
Background |
CSF2, that is, granulocyte-macrophage colony-stimulating factor (GM-CSF) , was originally found to be a hematopoietic growth factor that regulates the proliferation and differentiation of myeloid progenitor cells into granulocytes and macrophages, and it is also a hematopoietic growth factor that regulates the proliferation and differentiation of myeloid progenitor cells into macrophages, it has been confirmed that as a key proinflammatory cytokine, it can bind to receptors to activate multiple downstream inflammatory signaling pathways and regulate the activation, proliferation and effector functions of myeloid cells, in autoimmune diseases such as rheumatoid arthritis, its expression level is positively correlated with the severity of the disease, and it is a core factor driving the formation of inflammatory microenvironment and tissue damage in the lesion site, it has also become an important therapeutic target in the field of autoimmune diseases, and otilimab is a high-affinity anti-CSF2 human monoclonal antibody developed by glaxosmithkline based on this target, it inhibits downstream inflammatory signaling by specifically neutralizing CSF2 and blocking its interaction with cell surface receptor. |
|
Storage |
Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
|
Formulation |
Supplied as a 0.2 μm filtered solution of PBS, pH 7.2-7.4. |
|
Endotoxin |
< 1 EU/mg, determined by LAL gel clotting assay
|
